CELSION Retains Cameron Associates as Investor Relations Advisor
Columbia, MD - September 18, 2007: CELSION CORPORATION (AMEX: CLN) today announced that it has retained Cameron Associates, Inc. as its investor relations advisor. Cameron Associates is a 30-year-old New York-based, full-service investor relations firm that represents a wide variety of publicly-held companies in the U.S.
"Celsion is leveraging its technology platform to encapsulate and deliver locally higher concentrations of proven chemotherapeutic drugs," said Michael Tardugno, President and Chief Executive Officer. "Our immediate focus is to achieve two objectives: the clinical success and regulatory approval for our initial drug, ThermoDox, while at the same time, identifying and developing an oncology drug pipeline that addresses a range of indications.
"Our story is compelling, but relatively new. We believe Cameron will help us engage the investment community, gaining greater visibility and a growing understanding for our company as we achieve a number of significant milestones in the months and quarters ahead," concluded Mr. Tardugno.
About Cameron Associates
Founded in 1976, Cameron Associates, Inc. is a New York City-based, full-service investor relations firm providing strategic counsel to a select group of public companies. The firm is particularly focused on assisting emerging companies in the U.S. who need guidance in achieving key business goals, such as improved visibility and reputation in the equity markets, proper positioning of complex financial transactions, and communicating critical corporate issues. Additional information about Cameron Associates can be found on the company's web site at www.cameronassoc.com.
About Celsion:
Celsion is dedicated to the development and commercialization of oncology drugs including tumor-targeting treatments using focused heat energy in combination with heat activated drug delivery systems. Celsion has research, license or commercialization agreements with leading institutions such as the National Institutes of Health, Duke University Medical Center, University of Hong Kong, Cleveland Clinic, North Shore Long Island Jewish Health System. Additional information about Celsion Corporation can be found on the Celsion web site at www.celsion.com.
Celsion wishes to inform readers that forward-looking statements in this release are made pursuant to the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Readers are cautioned that such forward-looking statements involve risks and uncertainties including, without limitation, unforeseen changes in the course of research and development activities and in clinical trials by others; possible acquisitions of other technologies, assets or businesses; possible actions by customers, suppliers, competitors, regulatory authorities; and other risks detailed from time to time in the Company's periodic reports filed with the Securities and Exchange Commission.
For Further Information Contact:
Tony Deasey
Celsion Corporation
410.290.5390
tony@celsion.com
Paul G. Henning
Cameron Associates
212-554-5462
phenning@cameronassoc.com
